Aura Biosciences reports a Q2 GAAP loss of $0.48 per share, missing estimates by $0.10 as cash reserves extend runway to early 2029.
Aura Biosciences reported a second-quarter GAAP loss of $0.48 per share, exceeding analyst expectations by $0.10. The wider-than-anticipated loss reflects ongoing operational costs as the company advances its pipeline.
As of June 30, 2026, Aura held $323.8 million in cash, cash equivalents, and marketable securities. The company stated these funds are sufficient to support operations into the first half of 2029, providing a longer runway amid development efforts.
Shares showed limited immediate reaction in after-hours trading, with investors focusing on the cash position and timeline rather than the earnings miss.